Compounds > allocolchicine
Page last updated: 2024-09-26

allocolchicine

Description

allocolchicine: not allo-isomer of colchicine; structure given in first source; RN given refers to (S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID347381
CHEMBL ID52480
SCHEMBL ID13840934
MeSH IDM0102015

Synonyms (13)

Synonym
smr001566718
NCI60_003850
allocolchicine
nsc406042
mls002702901 ,
nsc-406042
CHEMBL52480 ,
bdbm50409016
SCHEMBL13840934
dibenzo[b,d]cycloheptamine, n-acetyl-1,2,3-trimethoxy-9-carbmethoxy-
methyl 5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5h-dibenzo[a,c]cycloheptene-3-carboxylate #
NMKUAEKKJQYLHK-UHFFFAOYSA-N
methyl 8-acetamido-13,14,15-trimethoxytricyclo[9.4.0.02,7]pentadeca-1(15),2(7),3,5,11,13-hexaene-5-carboxylate

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency0.01950.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency0.39810.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency70.79460.00018.4406100.0000AID720580
IDH1Homo sapiens (human)Potency0.00650.005210.865235.4813AID686970
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.25930.00419.984825.9290AID504444
gemininHomo sapiens (human)Potency0.10390.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tubulin alpha-1A chainSus scrofa (pig)IC50 (µMol)1.41250.00672.160310.0000AID214887
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID214887Inhibition of tubulin polymerization interacting at the colchicine binding site.2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Antitumor agents. 199. Three-dimensional quantitative structure-activity relationship study of the colchicine binding site ligands using comparative molecular field analysis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (11.11)18.7374
1990's7 (19.44)18.2507
2000's13 (36.11)29.6817
2010's10 (27.78)24.3611
2020's2 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
colchicine[no description available]medium310alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
thiocholchicine[no description available]medium20
2-demethylthiocolchicine[no description available]medium10
3-demethylthiocolchicine[no description available]medium10
n-acetylcolchinol o-methyl ether[no description available]medium30
propargyl alcohol[no description available]medium10propynol;
terminal acetylenic compound;
volatile organic compound		antifungal agent;
Saccharomyces cerevisiae metabolite
diphenyl[no description available]medium10aromatic fungicide;
benzenes;
biphenyls		antifungal agrochemical;
antimicrobial food preservative
taxane[no description available]medium10diterpene;
terpenoid fundamental parent
irofulven[no description available]medium10cyclohexenones
rhizoxin[no description available]medium101,3-oxazoles;
epoxide;
macrolide antibiotic		antimitotic;
antineoplastic agent;
metabolite
nsc 83265[no description available]medium10benzenoid aromatic compound
cysteine[no description available]medium10cysteiniumfundamental metabolite
sesquiterpenes[no description available]medium10
hydroquinone[no description available]medium10benzenediol;
hydroquinones		antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent
palladium[no description available]medium20metal allergen;
nickel group element atom;
platinum group metal atom
5,5'-bis(8-(phenylamino)-1-naphthalenesulfonate)[no description available]medium10
guanosine triphosphate[no description available]medium20guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
guanosine diphosphate[no description available]medium20guanosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
hexylene glycol[no description available]medium10glycol
glycerol[no description available]medium10alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
tropolone[no description available]medium20alpha-hydroxy ketone;
cyclic ketone;
enol		bacterial metabolite;
fungicide;
toxin
2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone[no description available]medium10
podophyllotoxin[no description available]medium10furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
rhazinilam[no description available]medium10
2-methoxytropolone[no description available]medium10
n-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide[no description available]medium10aminoxyls;
dicarboximide;
maleimides;
pyrrolidines
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms0low10
Cancer0low10
Cancer of Pancreas0low10
Cancer of the Pancreas0low10
Inflammation0low10
Innate Inflammatory Response0low10
Leukemia, Lymphocytic, T Cell0low10
Leukemia, Lymphocytic, T-Cell0low10
Leukemia, T-Cell0low10
Lymphocytic Leukemia, T-Cell0low10
Malignancy0low10
Malignant Neoplasms0low10
Necrosis0low10
Neoplasia0low10
Neoplasm0low10
Neoplasms0low10
Neoplasms, Benign0low10
Neoplasms, Pancreatic0low10
Pancreas Cancer0low10
Pancreas Neoplasms0low10
Pancreatic Cancer0low10
Pancreatic Neoplasms0low10
T Lymphocytic Leukemia0low10
T-Cell Leukemia0low10
T-Lymphocytic Leukemia0low10
Tumors0low10

Research Highlights

Interactions (1)

ArticleYear
Enhanced antitumor activity of irofulven in combination with antimitotic agents.
Investigational new drugs, Volume: 20, Issue: 3		2002
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]